Stock Events

Stock Events

Valneva 

$3.29
699
+$0.52+18.77% Monday 20:00

Statistics

Day High
2.77
Day Low
2.77
52W High
5.9
52W Low
2.43
Volume
89
Avg. Volume
39
Mkt Cap
311.97M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.27
-0.2
-0.13
-0.06
Expected EPS
-0.08474621652
Actual EPS
N/A

Financials

-74.21%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
181.12MRevenue
-134.4MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow INRLF. It's not an investment recommendation.
TotalEnergies
66
TTE.PA
Air Liquide
51
AI.PA
Lvmh Moet Hennessy Louis Vuitton
38
MC.PA
Axa
38
CS.PA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novavax
NVAX
Mkt Cap1.53B
Novavax is a competitor because it also focuses on the development of vaccines for infectious diseases, similar to Valneva's core business.
Moderna
MRNA
Mkt Cap55.09B
Moderna is a competitor in the vaccine space, particularly for its mRNA technology platform that can target various infectious diseases, competing with Valneva's vaccine development efforts.
BioNTech
BNTX
Mkt Cap25.64B
BioNTech competes with Valneva in the development and commercialization of vaccines, with a strong focus on mRNA technology.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a global pharmaceutical company with a broad portfolio that includes vaccines, directly competing with Valneva's vaccine products.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline is a competitor due to its large vaccine division, which produces vaccines for a range of infectious diseases, overlapping with Valneva's market.
Sanofi
SNY
Mkt Cap107.39B
Sanofi competes with Valneva in the vaccine market, with a wide range of vaccines for infectious diseases, including those in direct competition with Valneva's products.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its Janssen Pharmaceuticals division, develops vaccines and therapeutics that compete with Valneva's product offerings.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca is involved in the development and commercialization of vaccines, including those for infectious diseases, making it a competitor to Valneva.
Incyte
INCY
Mkt Cap25.21B
Incyte Corporation, while primarily focused on oncology, also has efforts in immunology that could potentially compete with Valneva's infectious disease vaccine portfolio.

About

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Show more...
CEO
Thomas Lingelbach
Employees
674
Country
France
ISIN
FR0004056851
WKN
000A0MVJZ

Listings

STU
DE
AYJ.STU
STU
DE
AYJ0.STU
F
DE
AYJ.F
MU
DE
AYJ0.MU

0 Comments

Share your thoughts

FAQ

What is Valneva stock price today?▼
The current price of INRLF is $3.29 USD — it has increased by +18.77% in the past 24 hours. Watch Valneva stock price performance more closely on the chart.
What is Valneva stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Valneva stocks are traded under the ticker INRLF.
Is Valneva stock price growing?▼
INRLF stock has risen by +18.77% compared to the previous week, the month change is a +35.39% rise, over the last year Valneva has showed a -23.04% decrease.
What is Valneva market cap?▼
Today Valneva has the market capitalization of 311.97M
When is the next Valneva earnings date?▼
Valneva is going to release the next earnings report on November 12, 2026.
What were Valneva earnings last quarter?▼
INRLF earnings for the last quarter are -0.19 USD per share, whereas the estimation was -0.1 USD resulting in a -91.03% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Valneva revenue for the last year?▼
Valneva revenue for the last year amounts to 181.12M USD.
What is Valneva net income for the last year?▼
INRLF net income for the last year is -134.4M USD.
How many employees does Valneva have?▼
As of September 04, 2026, the company has 674 employees.
In which sector is Valneva located?▼
Valneva operates in the Health & Wellness sector.
When did Valneva complete a stock split?▼
Valneva has not had any recent stock splits.
Where is Valneva headquartered?▼
Valneva is headquartered in Saint-Herblain, France.